[
  {
    "ts": null,
    "headline": "Aktis Oncology Jumps 27% After $318 Million Upsized IPO",
    "summary": "Shares traded at $22.91 after pricing at $18, valuing the clinical-stage biotech at about $1.2 billion.",
    "url": "https://finnhub.io/api/news?id=2e41725c876564c1c84edf6b7aa6d6f8bf9bf049d82123622c0aad2aa0af0a23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767983099,
      "headline": "Aktis Oncology Jumps 27% After $318 Million Upsized IPO",
      "id": 138052205,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Shares traded at $22.91 after pricing at $18, valuing the clinical-stage biotech at about $1.2 billion.",
      "url": "https://finnhub.io/api/news?id=2e41725c876564c1c84edf6b7aa6d6f8bf9bf049d82123622c0aad2aa0af0a23"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
    "summary": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
    "url": "https://finnhub.io/api/news?id=24cd194a3a20b8e0867da9447639c2a8763dc564d568cdccc20d2e295e9e3b46",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767981556,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
      "id": 138050125,
      "image": "",
      "related": "MDT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=24cd194a3a20b8e0867da9447639c2a8763dc564d568cdccc20d2e295e9e3b46"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
    "summary": "It could be another tough year for the once-soaring drugmaker.",
    "url": "https://finnhub.io/api/news?id=671086fc2166b8182cea8c946e5ccae67960b29adc6b689890d9c99fb800b77f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767970200,
      "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
      "id": 138046728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "It could be another tough year for the once-soaring drugmaker.",
      "url": "https://finnhub.io/api/news?id=671086fc2166b8182cea8c946e5ccae67960b29adc6b689890d9c99fb800b77f"
    }
  },
  {
    "ts": null,
    "headline": "Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries?",
    "summary": "ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.",
    "url": "https://finnhub.io/api/news?id=9f0ada614bd8274eb02d11f07d8bb271bfc5a48c4000e0e2190929799427090c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767968160,
      "headline": "Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries?",
      "id": 138046639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.",
      "url": "https://finnhub.io/api/news?id=9f0ada614bd8274eb02d11f07d8bb271bfc5a48c4000e0e2190929799427090c"
    }
  },
  {
    "ts": null,
    "headline": "Intuitive Surgical: An Easy 'Buy And Hold' For Long-Term Outperformance",
    "summary": "Intuitive Surgical, Inc. stock: da Vinci robotics leader with 80% share, recurring revenue, fast procedure growth and solid moat. Click for why I'm bullish on ISRG.",
    "url": "https://finnhub.io/api/news?id=3940a55a0446df16a9a7623ab9e49dfe85249f8a94252e669e465ab7d0d16bd7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767953808,
      "headline": "Intuitive Surgical: An Easy 'Buy And Hold' For Long-Term Outperformance",
      "id": 138046165,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405174420/image_1405174420.jpg?io=getty-c-w1536",
      "related": "MDT",
      "source": "SeekingAlpha",
      "summary": "Intuitive Surgical, Inc. stock: da Vinci robotics leader with 80% share, recurring revenue, fast procedure growth and solid moat. Click for why I'm bullish on ISRG.",
      "url": "https://finnhub.io/api/news?id=3940a55a0446df16a9a7623ab9e49dfe85249f8a94252e669e465ab7d0d16bd7"
    }
  }
]